Evidence map›Paper›PMID 34085774›Full record

ArticleESC heart failure2021

Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.

Carolin Gehlken, Elles M Screever, Navin Suthahar, Peter van der Meer, B Daan Westenbrink, Jennifer E Coster, Dirk J Van Veldhuisen, Rudolf A de Boer, Wouter C Meijers

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07270367 (Finerenone and Cardiac Remodeling), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07270367 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Finerenone and Cardiac Remodeling: A Randomized, Double- Blind, Placebo-Controlled Study to Evaluate The Effects of Finerenone on Ventricular Remodeling

TypeinterventionalSponsorSubodh VermaRan2025 to 2030Enrolled156ConditionsHeart FailureArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Comorbidities complicating heart failure: changes over the last 15 years.Clinical research in cardiology : official journal of the German Cardiac Society · 2023
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Carolin GehlkenDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Elles M ScreeverDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Navin SuthaharDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Peter van der MeerDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
B Daan WestenbrinkDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Jennifer E CosterDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Dirk J Van VeldhuisenDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Rudolf A de BoerDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
Wouter C MeijersDepartment of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), PO Box 30.001, Groningen, 9700 RB, The Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTwo key echocardiographic parameters that are currently used to diagnose heart failure (HF) with preserved ejection fraction (HFpEF) are left atrial volume index (LAVi) and left ventricular mass index (LVMi). We investigated whether patients' characteristics, biomarkers, and co-morbidities are associated with these parameters and whether the relationships differ between patients with HFpEF or HF with reduced ejection fraction (HFrEF).

methodsWe consecutively enrolled 831 outpatients with typical signs and symptoms of HF and elevated N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels and categorized patients based upon left ventricular ejection fraction (LVEF): LVEF < 40% (HFrEF), LVEF between 40% and 50% (HF with mid-range ejection fraction), and LVEF ≥ 50% (HFpEF). The study includes consecutively enrolled HF patients from an HF outpatient clinic at a tertiary medical centre in the Netherlands. All patients underwent baseline characterization, laboratory measurements, and echocardiography.

resultsFour hundred sixty-nine patients had HFrEF, 189 HF with mid-range ejection fraction, and 173 HFpEF. The patients with HFrEF were rather male [HFrEF: 323 (69%); HFpEF: 80 (46%); P < 0.001], and the age was comparable (HFrEF 67 ± 13; HFpEF 70 ± 14; P = 0.069). In HFpEF, more patients had hypertension [190 (40.5%); 114 (65.9%); P < 0.001], higher body mass indices (27 ± 8; 30 ± 7; P < 0.001), and atrial fibrillation [194 (41.4); 86 (49.7); P = 0.029]. The correlation analyses showed that in HFrEF patients, LAVi was significantly associated with age (β 0.293; P < 0.001), male gender (β 0.104; P = 0.042), body mass index (β -0160; P = 0.002), diastolic blood pressure (β -0.136; P < 0.001), New York Heart Association (β 0.174; P = 0.001), atrial fibrillation (β 0.381; P < 0.001), galectin 3 (β 0.230; P < 0.001), NT-proBNP (β 0.183; P < 0.001), estimated glomerular filtration rate (β -0.205; P < 0.001), LVEF (β -0.173; P = 0.001), and LVMi (β 0.337; P < 0.001). In HFpEF patients, only age (β 0.326; P < 0.001), atrial fibrillation (β 0.386; P < 0.001), NT-proBNP (β 0.176; P = 0.036), and LVMi (β 0.213; P = 0.013) were associated with LAVi.

conclusionsAlthough LVMi and LAVi are hallmark parameters to diagnose HFpEF, they only correlate with a few characteristics of HF and mainly with atrial fibrillation. In contrast, in HFrEF patients, LAVi relates strongly to several other HF parameters. These findings underscore the complexity in visualizing the pathophysiology of HFpEF and question the relation between cardiac structural remodeling and the impact of co-morbidities.

Indexed as

Heart FailureHeart AtriaHumansMalePrognosisStroke VolumeVentricular Function, LeftBiomarkersEchocardiographyHeart failure with preserved ejection fraction (HFpEF)Left atrial volume index (LAVi)Left ventricular mass index (LVMi)NT-proBNP

Identifiers

PMID34085774
PMCPMC8318400
OpenAlexW3165187768

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.